C07K 2317/565
Complementarity determining region [cdr]
Official title: Complementarity determining region [CDR]
C07K2317/565 (Complementarity determining region [cdr]) appears on 9,148 US grants and 16,956 published applications in this corpus.
Search patents in C07K- Granted patents
- 9,148
- Published applications
- 16,956
- Assignees
- 3,517
- Inventors
- 23,387
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 5 | 0 |
| 1997 | 5 | 0 |
| 1998 | 9 | 0 |
| 1999 | 16 | 0 |
| 2000 | 15 | 0 |
| 2001 | 17 | 4 |
| 2002 | 20 | 29 |
| 2003 | 17 | 95 |
| 2004 | 23 | 113 |
| 2005 | 20 | 164 |
| 2006 | 42 | 172 |
| 2007 | 56 | 173 |
| 2008 | 85 | 185 |
| 2009 | 97 | 365 |
| 2010 | 173 | 402 |
| 2011 | 214 | 490 |
| 2012 | 297 | 485 |
| 2013 | 353 | 503 |
| 2014 | 340 | 604 |
| 2015 | 419 | 696 |
| 2016 | 513 | 877 |
| 2017 | 543 | 919 |
| 2018 | 571 | 881 |
| 2019 | 612 | 915 |
| 2020 | 672 | 1139 |
| 2021 | 658 | 1296 |
| 2022 | 650 | 1267 |
| 2023 | 595 | 1394 |
| 2024 | 734 | 1424 |
| 2025 | 805 | 1308 |
| 2026 | 572 | 1056 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- NKG2A-targeting antibody and use thereof6 Oct 2026US 12,753,231 B2Bioheng Therapeutics Limited
- Canine PD-L1 antibody, antigen binding fragments thereof, and methods of use thereof6 Oct 2026US 12,753,234 B2Purdue Research Foundation
- Antibody recognizing extracellular region of ALK2/ACVR16 Oct 2026US 12,753,237 B2Saitama Medical University
- Anti-tumor necrosis factor receptor (TNFR2) antibodies and uses thereof6 Oct 2026US 12,753,240 B2Biolojic Design Ltd.
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Pediatric dosage and administration of anti-c5 antibodies for treatment of complement disorders8 Oct 2026US 2026/0308238 A1Alexion Pharmaceuticals, Inc.
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Polynucleotides encoding improved humanized immunoglobulins1,258US 5,693,761 AProtein Design Labs, Inc. · 1997